Compare PAMT & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAMT | AGEN |
|---|---|---|
| Founded | 1980 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.4M | 274.8M |
| IPO Year | 1995 | 1999 |
| Metric | PAMT | AGEN |
|---|---|---|
| Price | $11.87 | $8.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $26.33 |
| AVG Volume (30 Days) | 12.3K | ★ 960.9K |
| Earning Date | 10-27-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 0.96 |
| Revenue | ★ $437,838,000.00 | $42,877,086.00 |
| Revenue This Year | $17.76 | $9.64 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $10.30 |
| Revenue Growth | 1.15 | ★ 89.95 |
| 52 Week Low | $7.15 | $2.71 |
| 52 Week High | $17.75 | $10.06 |
| Indicator | PAMT | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 39.33 | N/A |
| Support Level | $10.72 | N/A |
| Resistance Level | $13.04 | N/A |
| Average True Range (ATR) | 0.80 | 0.00 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 15.83 | 0.00 |
PAMT Corp is a holding company that is engaged in providing truckload dry van carrier services transporting general commodities throughout the continental United States and Mexico, as well as in certain Canadian provinces. Its freight consists of automotive parts, expedited goods, consumer goods, such as general retail store merchandise, and manufactured goods, such as heating and air conditioning units. It has one reportable segment being motor carrier.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.